We are live on ! Find out more
NVO

Novo Nordisk

1,395 hedge funds and large institutions have $16.7B invested in Novo Nordisk in 2025 Q3 according to their latest regulatory filings, with 159 funds opening new positions, 502 increasing their positions, 550 reducing their positions, and 224 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.23% less ownership

Funds ownership: 9.1%8.87% (-0.23%)

9% less repeat investments, than reductions

Existing positions increased: 502 | Existing positions reduced: 550

6% less funds holding

Funds holding: 1,4811,395 (-86)

22% less capital invested

Capital invested by funds: $21.3B → $16.7B (-$4.59B)

29% less first-time investments, than exits

New positions opened: 159 | Existing positions closed: 224

32% less call options, than puts

Call options by funds: $2.04B | Put options by funds: $2.99B

32% less funds holding in top 10

Funds holding in top 10: 2517 (-8)

Holders
1,395
Holders Change
-86
Holders Change %
-5.81%
% of All Funds
18.31%
Holding in Top 10
17
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-32%
% of All Funds
0.22%
New
159
Increased
502
Reduced
550
Closed
224
Calls
$2.04B
Puts
$2.99B
Net Calls
-$946M
Net Calls Change
-$454M
Name Holding Trade Value Shares
Change
Change in
Stake
PF
226
Phoenix Financial
Israel
$5.91M +$3.05M +52,168 +96%
AC
227
Arrow Capital
Australia
$5.87M +$4.1M +70,000 New
SFM
228
Sphera Funds Management
Israel
$5.86M
BM
229
Bridger Management
New York
$5.72M -$81.1K -1,386 -1%
SPIA
230
Steward Partners Investment Advisory
New York
$5.71M -$2.07M -35,302 -26%
HTIM
231
Harbour Trust & Investment Management
Indiana
$5.64M -$273K -4,665 -4%
New York State Common Retirement Fund
232
New York State Common Retirement Fund
New York
$5.59M -$1.14M -19,550 -16%
MIP
233
Marietta Investment Partners
Wisconsin
$5.51M -$1.33M -22,649 -19%
AI
234
Aperture Investors
New York
$5.5M +$2.07M +35,317 +55%
XI
235
XXEC Inc
Oklahoma
$5.5M +$1.22M +20,890 +27%
ASN
236
Advisory Services Network
Georgia
$5.49M +$623K +10,642 +12%
BIA
237
Biondo Investment Advisors
Pennsylvania
$5.47M +$406K +6,940 +8%
PGFC
238
Peapack-Gladstone Financial Corp
New Jersey
$5.45M +$1.32M +22,525 +30%
GSCM
239
Greenfield Seitz Capital Management
Texas
$5.38M +$758K +12,948 +15%
SIM
240
Stratos Investment Management
Ohio
$5.37M +$431K +7,356 +8%
Victory Capital Management
241
Victory Capital Management
Texas
$5.31M -$59.9M -1,024,146 -91%
SAM
242
Smithbridge Asset Management
Pennsylvania
$5.24M +$167K +2,845 +3%
AP
243
Arlington Partners
Alabama
$5.16M +$1.58M +26,928 +41%
Allspring Global Investments
244
Allspring Global Investments
North Carolina
$5.15M -$443K -7,570 -8%
USCWA
245
U.S. Capital Wealth Advisors
Texas
$5.14M +$2.62M +44,707 +93%
EB
246
Eastern Bank
Massachusetts
$5.06M +$90K +1,537 +2%
NC
247
Nicholas Company
Wisconsin
$5.04M +$5.32M +90,890 New
SCP
248
Shorepoint Capital Partners
Massachusetts
$4.84M +$5.1M +87,191 New
WS
249
Wedbush Securities
California
$4.75M -$40.6K -694 -0.8%
S
250
SimplyRich
California
$4.7M -$456K -7,782 -8%

NVO Hedge Fund Activity: Q3 2025 in Review

1,395 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2025, worth a combined $16.7B — down 22% from $21.3B a quarter earlier.

Sellers outnumbered buyers: 224 funds closed out of NVO and 159 opened new positions — a net loss of 65 holders — while 550 trimmed existing stakes and 502 added.

The largest buyer was Franklin Resources, adding an estimated $800M. The largest seller was Jennison Associates, cutting an estimated $1.03B.

  • 1,395 institutional investors held Novo Nordisk (NVO) as of Q3 2025, down from 1,481 in Q2 2025.
  • Funds reported $16.7B of Novo Nordisk stock for Q3 2025, down 22% quarter-over-quarter.
  • 159 funds opened new Novo Nordisk positions in Q3 2025 and 224 closed out, a net change of -65 holders.
  • The largest Novo Nordisk buyer in Q3 2025 was Franklin Resources, an estimated $800M added.
  • The largest Novo Nordisk seller in Q3 2025 was Jennison Associates, an estimated $1.03B sold.

Based on aggregated 13F filings for Q3 2025.